Indications for: BARHEMSYS

Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.

Adult Dosage:

Prevention: 5mg as a single IV inj infused over 1–2mins at the time of induction of anesthesia. Treatment: 10mg as a single IV inj infused over 1–2mins in the event of nausea and/or vomiting after a surgical procedure.

Children Dosage:

Not established.

BARHEMSYS Warnings/Precautions:

Risk of QT prolongation. Avoid in congenital long QT syndrome. Monitor ECG in those with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), CHF, or other medical conditions known to prolong the QT interval. Severe renal impairment (eGFR <30mL/min/1.73m2): avoid. Pregnancy. Nursing mothers: consider interrupting breastfeeding or pumping/discarding breast milk for 48hrs after dose.

BARHEMSYS Classification:

Dopamine-2 receptor antagonist.

BARHEMSYS Interactions:

Avoid concomitant droperidol, levodopa. Concomitant other drugs known to prolong the QT interval (eg, ondansetron): monitor ECG.

Adverse Reactions:

Increased blood prolactin concentrations, chills, hypokalemia, procedural hypotension, abdominal distension, infusion site pain.

Generic Drug Availability:


How Supplied:

Single-dose vial (2mL)—10